ATR and ovarian carcinoma: Therefore, NUSAP1 in ovarian cancer may participate in HRR by regulating the levels of ATR and BRCA1/2; thus, low expression of NUSAP1 in ovarian cancer implies sensitivity to PARP inhibitors.